Listen to Medscape InDiscussion: Lung Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for o...
Drs Jacob Sands and Jia Luo discuss NUT carcinoma, including diagnostic challenges, emerging treatments, clinical trial options, and the NUT carcinoma registry. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999032. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics https://pubmed.ncbi.nlm.nih.gov/35372003/ The MYC Oncogene — The Grand Orchestrator of Cancer Growth and Immune Evasion https://pubmed.ncbi.nlm.nih.gov/34508258/ SOX2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype https://pubmed.ncbi.nlm.nih.gov/34593608/ Next-Generation Sequencing in Cancer https://pubmed.ncbi.nlm.nih.gov/34408360/ PET Scanning https://www.ncbi.nlm.nih.gov/books/NBK559089/ Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma https://pubmed.ncbi.nlm.nih.gov/38154515/ International NUT Carcinoma Registry https://nc-registry.org/ Automated Tumor Proportion Score Analysis for PD-L1 (22C3) Expression in Lung Squamous Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/34354151/ Ewing Sarcoma https://emedicine.medscape.com/article/990378-overview?form=fpf Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication https://www.medscape.com/viewarticle/999028 BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications https://pubmed.ncbi.nlm.nih.gov/37049806/ Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma https://clinicaltrials.gov/study/NCT05019716 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors https://clinicaltrials.gov/study/NCT05372640 Development of CDK4/6 Inhibitors: A Five Years Update https://pubmed.ncbi.nlm.nih.gov/33803309/ A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma https://www.clinicaltrials.gov/search?cond=NCT04718675 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors https://clinicaltrials.gov/study/NCT05488548
--------
27:00
S3 Episode 5: Revolutionizing Small Cell Lung Cancer: A Deep Dive into Immunotherapy Advancements With Dr Hossein Borghaei
Drs Jacob Sands and Hossein Borghaei discuss small cell lung cancer, including breakthroughs and challenges in immunotherapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999031. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280641/ Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31590988/ Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/ Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort https://pubmed.ncbi.nlm.nih.gov/31629915/ Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/25891174/ Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer (KEYNOTE-001): 3-Year Results From an Open-Label, Phase 1 Study https://pubmed.ncbi.nlm.nih.gov/30876831/ Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/10080612/ Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17135646/ Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://pubmed.ncbi.nlm.nih.gov/32224306/ Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group https://pubmed.ncbi.nlm.nih.gov/21115872/ Beyond Overall Survival: Considering Quality of Life in the Treatment of Early Non-Small Cell Lung Cancer https://www.medscape.com/viewarticle/999479 Tarlatamab for Patients With Previously Treated Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37861218/
--------
26:00
S3 Episode 4: The Future of Antibody-Drug Conjugates in Lung Cancer Treatment
Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999030. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress https://pubmed.ncbi.nlm.nih.gov/37163707/ TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) https://pubmed.ncbi.nlm.nih.gov/37230055/ Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan https://pubmed.ncbi.nlm.nih.gov/28548889/ Gilead Provides Update on Phase 3 EVOKE-01 Study https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/gilead-provides-update-on-phase-3-evoke-01-study EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non–Small Cell Lung Cancer (NSCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS9146 Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC https://dailyreporter.esmo.org/esmo-congress-2023/non-small-cell-lung-cancer/datopotamab-deruxtecan-met-the-pfs-endpoint-in-previously-treated-nsclc Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/ Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial https://pubmed.ncbi.nlm.nih.gov/37694347/ Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/36288547/ Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint https://www.globenewswire.com/news-release/2023/12/21/2799759/0/en/Press-Release-Sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2L-NSCLC-Phase-3-trial-did-not-meet-a-primary-endpoint.html Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? https://pubmed.ncbi.nlm.nih.gov/37370772/ BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study https://meetings.asco.org/abstracts-presentations/218492
--------
28:19
S3 Episode 3: Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health
Drs Jacob Sands and Narjust Florez discuss the nuances of treating women with lung cancer, including screening, treatment, and sexual and reproductive health. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999029). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference? https://www.medscape.com/viewarticle/969537 Higher Lung Cancer Incidence in Young Women Than Young Men in the United States https://pubmed.ncbi.nlm.nih.gov/29791813/ Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37843054/ EGFR Resisters https://egfrcancer.org/ GO2 for Lung Cancer https://go2.org/
--------
26:00
S3 Episode 2: Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication
Drs Jacob Sands and Donald L. Rosenstein discuss the psychology of lung cancer and how to effectively communicate with patients about diagnosis, treatment, and expectations. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2 The Flourishing Scholarship of Psychosocial Oncology Viewed Across 30 Years Through the Lens of This Journal, Psycho-Oncology https://pubmed.ncbi.nlm.nih.gov/35396891/ Living With and Beyond Cancer: Psychosocial and Psychological Support for Patients From Diagnosis Through Survivorship https://www.medscape.com/viewarticle/985096 "Scanxiety" and a Sense of Control: The Perspective of Lung Cancer Survivors and Their Caregivers on Follow-up - A Qualitative Study https://pubmed.ncbi.nlm.nih.gov/37069692/ Psychotherapy Alone Versus Collaborative Psychotherapy and Psychiatric Care in the Treatment of Depression and Anxiety in Patients With Cancer: A Naturalistic, Observational Study https://pubmed.ncbi.nlm.nih.gov/37209423/ Creating a Proactive Interdisciplinary Approach to Care: Embedding Oncology Care Coordination Within an Oncology Patient and Family Support Program https://ascopubs.org/doi/10.1200/JCO.2022.40.28_suppl.051 Use of PHQ-9 for Monitoring Patients With Depression in Integrated Primary Care Practices https://pubmed.ncbi.nlm.nih.gov/36693193/ Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting https://pubmed.ncbi.nlm.nih.gov/32582485/ Implementing Collaborative Care for Major Depression in a Cancer Center: An Observational Study Using Mixed-Methods https://pubmed.ncbi.nlm.nih.gov/35305403/
Listen to Medscape InDiscussion: Lung Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Portugal